Daniel A. Goldstein, MD, of Emory University and Rabin Medical Center, discusses his study findings that show nearly $1 billion in savings when patients receive personal weight-based doses instead of a predetermined fixed dose for treatment of PD-L1-positive non–small cell lung cancer. (Abstract 9013)
Greta Stifel recounts her story about a misdiagnosed tumor and urges physicians to raise awareness of neuroendocrine disease.
Gary Rodin, MD, of the University of Toronto, discusses study findings on a systematic approach to alleviating distress and managing predictable challenges. (Abstract LBA10001)
Maura L. Gillison, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses her findings on the impact of prophylactic human papillomavirus vaccination on oral HPV infections among young adults in the United States. (Abstract 6003)
Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)
Lisa A. Carey, MD, of the University of North Carolina, and Nadia Harbeck, MD, PhD, of Brustzentrum der Universität München, discuss study findings on adjuvant 4xEC→4x doc vs 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Abstract 504)
